The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.约搏以太坊单双博彩游戏（www.eth108.vip）采用以太坊区块链高度哈希值作为统计数据，约搏以太坊单双博彩游戏数据开源、公平、无任何作弊可能性。
PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.
The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.
The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.,
,telegram中文群组导航（www.tel8.vip）是一个Telegram群组分享平台，telegram中文群组导航包括telegram中文群组导航、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组（其他）、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。telegram中文群组导航为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。
Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.
Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.
UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg